A Phase II Study of Durvalumab in Patients With Mismatch Repair Deficient or POLE Mutated Metastatic Colorectal Cancer
Phase of Trial: Phase II
Latest Information Update: 15 May 2018
At a glance
- Drugs Durvalumab (Primary)
- Indications Adenocarcinoma; Colon cancer; Rectal cancer
- Focus Therapeutic Use
- 03 May 2018 Status changed from not yet recruiting to recruiting.
- 25 Feb 2018 Planned initiation date changed from 1 Mar 2018 to 5 Mar 2018.
- 19 Feb 2018 New trial record